“The rand would likely head towards R21.00/$ immediately and then weaken to beyond R22.00/$ depending on the new partners of the GNU, with the sudden shock to financial markets and worries over ...

The FDA states the purpose of Fast Track to get important new drugs to the patient earlier. HHT, an Orphan Disease, is the second most common inherited bleeding disorder in the world frequently ...

HHT is a severely debilitating bleeding disorder caused by mutations in ALK1 or Endoglin genes. These mutations lead to severe nosebleeds and gastrointestinal bleeds that lead to transfusion ...

Significant reduction seen in epistaxis severity with pomalidomide treatment for patients with HHT. HealthDay News — For patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide ...

Pomalidomide, a cancer medication, has been revealed in a clinical trial to be safe and efficacious in treating hereditary hemorrhagic telangiectasia (HHT). This rare bleeding disorder affects ...

The double-blind, randomized trial, led by Keith McCrae, MD, director of benign hematology at Cleveland Clinic, demonstrated that HHT patients who were treated using pomalidomide experienced a ...

Hereditary hemorrhagic telangiectasia (HHT), the world's second-most-common inherited bleeding disorder, affects approximately 1-in-5,000 people and can have life-threatening complications ...

The therapy in question, a once-daily allosteric AKT inhibitor dubbed VAD044, was trialed in 75 patients with hereditary hemorrhagic telangiectasia (HHT), a genetic disorder that leads to abnormal ...

Trial delivers positive results in first ever industry-led clinical trial in Hereditary Haemorrhagic Telangiectasia (HHT) VAD044 showed favourable safety and tolerability, together with ...

HHT, an Orphan Disease, is the second most common inherited bleeding disorder in the world frequently causing severe disease burden, reduced life expectancy and impaired Quality of Life.